LONG-TERM EFFECT OF INTRAVITREAL BEVACIZUMAB (AVASTIN) IN PATIENTS WITH CHRONIC DIFFUSE DIABETIC MACULAR EDEMA

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Retina

• Publication date

  2008-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/IAE.0b013e318176de48PMID 18779710
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Medical Interventions for Diabetic Retinopathy

  2008cited by this paper
• Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients

  2008cited by this paper
• Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes.

  2007cited by this paper
• Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.

  2007cited by this paper
• Bevacizumab and retinal ischemia.

  2007cited by this paper
• Intravitreal bevacizumab for treatment of uveitic macular edema.

  2007cited by this paper
• A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.

  2007cited by this paper
• INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTION ALONE OR COMBINED WITH TRIAMCINOLONE VERSUS MACULAR PHOTOCOAGULATION AS PRIMARY TREATMENT OF DIABETIC MACULAR EDEMA

  2007cited by this paper
• INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE STUDY)

  2006cited by this paper
• Ranibizumab: Phase III clinical trial results.

  2006cited by this paper
• Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

  2006cited by this paper
• ELECTROPHYSIOLOGIC FINDINGS AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT

  2006cited by this paper
• Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.

  2006cited by this paper
• Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.

  2006cited by this paper
• INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF MACULAR EDEMA IN CENTRAL RETINAL VEIN OCCLUSION: A Short-Term Study

  2006cited by this paper
• TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)

  2006cited by this paper
• Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.

  2006cited by this paper
• INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY COMPLICATED BY VITREOUS HEMORRHAGE

  2006cited by this paper
• A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema.

  2006cited by this paper
• INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR PERSISTENT DIFFUSE DIABETIC MACULAR EDEMA

  2006cited by this paper
• Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema.

  2006cited by this paper
• Intravitreal Bevacizumab (Avastin) Treatment of Macular Edema in Central Retinal Vein Occlusion

  2006cited by this paper
• Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.

  2005cited by this paper
• Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion.

  2005cited by this paper
• A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.

  2005cited by this paper
• The role of bevacizumab as first-line therapy for colon cancer.

  2005cited by this paper
• Pegaptanib for neovascular age-related macular degeneration.

  2004cited by this paper
• VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2004cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• VEGF164 is proinflammatory in the diabetic retina.

  2003cited by this paper
• Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo.

  2002cited by this paper
• Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive insulin therapy, by The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N. Engl. J. Med 342:381-9, 2000.

  2001cited by this paper
• Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

  2000cited by this paper
• Diabetes in America: Epidemiology and Scope of the Problem

  1998cited by this paper
• The Diabetes Control and Complications Trial

  1998cited by this paper
• Increased expression of angiogenic growth factors in age-related maculopathy

  1997cited by this paper
• Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes.

  1996cited by this paper
• Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group.

  1991cited by this paper
• Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor.

  1990cited by this paper
• Vascular endothelial growth factor is a secreted angiogenic mitogen.

  1989cited by this paper
• Vascular permeability factor, an endothelial cell mitogen related to PDGF.

  1989cited by this paper
• Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.

  1985cited by this paper
• Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.

  1983cited by this paper
• [Early photocoagulation of diabetic retinopathy].

  1981cited by this paper

• Visual outcomes associated with optical coherence tomography biomarkers in diabetic macular edema: A systematic review.

  2025cites this paper
• Current pharmacologic modalities for diabetic macular edema

  2025cites this paper
• Multimodal imaging in diabetic retinopathy and macular edema: An update about biomarkers.

  2024cites this paper
• Management of treatment-naïve diabetic macular edema patients: Review of real-world clinical data

  2024cites this paper
• Comparative Analytical Study of Intravitreal Triamcinolone Acetonide Versus Bevacizumab in Managing Diabetic Macular Edema: Insights From a Tertiary Eye Care Facility in India

  2024cites this paper
• Factors Affecting Compliance and Visual Outcomes in Patients Receiving Intravitreal Bevacizumab Injections

  2024influential citation
• Peripheral and central capillary non-perfusion in diabetic retinopathy: An updated overview

  2023cites this paper
• Optical coherence tomography angiographic changes following loading phase with intravitreal aflibercept for diabetic macular edema.

  2022cites this paper
• Relationship Between Macular Thickness and Visual Acuity in the Treatment of Diabetic Macular Edema With Anti-VEGF Therapy: Systematic Review

  2022cites this paper
• Bevacizumab

  2021cites this paper
• Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy

  2021cites this paper
• COMPARATIVE EFFICACY OF INTRAVITREAL RANIBIZUMAB MONOTHERAPY WITH COMBINED INTRAVITREAL RANIBIZUMAB AND LASER PHOTOCOAGULATION THERAPY IN THE MANAGEMENT OF DIABETIC MACULAR EDEMA.

  2021cites this paper
• Short-Term Outcomes of Refractory Diabetic Macular Edema Switch From Ranibizumab to Dexamethasone Implant and the Influential Factors: A Retrospective Real World Experience

  2021cites this paper
• Real-world experience with pro re nata dosing of intravitreal dexamethasone implant for eyes with refractory diabetic macular edema

  2020cites this paper
• Visual outcomes in diabetic macular edema patients after avastin injection

  2020cites this paper
• Intravitreal anti-vascular endothelial growth factor medications during pregnancy: current perspective

  2020cites this paper
• Diyabetik Makula Ödeminde İntravitreal Bevacizumab Tedavisinin Santral Makula Kalınlığı Ve Santral Retina Duyarlılığı Üzerine Etkisi

  2020cites this paper
• Short-term Outcomes of Refractory Diabetic Macular Edema Switch from Ranibizumab to Dexamethasone Implant and the In uential Factors: A Retrospective Real World Experience

  2020cites this paper
• Association of macular perfusion status with microvascular parameters up to the far periphery in diabetic retinopathy using multimodal imaging

  2020cites this paper
• Characteristics of diabetic macular edema patients refractory to anti-VEGF treatments and a dexamethasone implant

  2019cites this paper
• Clinical Strategies in the Management of Diabetic Retinopathy

  2019influential citation
• Effect of Intravitreal Anti-Vascular Growth Factor Agents With or Without Macular Photocoagulation on Diabetic Macular Edema: A Systematic Review and Meta-Analysis

  2019cites this paper
• Soluble Tei2 fusion protein inhibits retinopathy of prematurity occurrence via regulation of the Ang/Tie2 pathway

  2019cites this paper
• Relationship Between Dry Retinal Volume and Visual Acuity in Diabetic Macular Edema.

  2018cites this paper
• Early Retinal and Choroidal Coat Thickness Changes after Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema

  2018cites this paper
• Inhibitory Effects On Retinal Neovascularization by Ranibizumab and sTie2-Fc in An Oxygen-Induced Retinopathy Mouse Model

  2018cites this paper
• Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies

  2018cites this paper
• Diabetic Macular Edema

  2018cites this paper
• Clinical Findings and Management of Pathological Myopic Degeneration with Secondary Choroidal

  2018cites this paper
• Evaluation of the Therapeutic Effect of Intravitreal Bevacizumab in Diabetic Macular Edema

  2018cites this paper
• Short-term effects of intravitreal bevacizumab in contrast sensitivity of patients with diabetic macular edema and optimizing glycemic control.

  2018cites this paper
• Effect of Intravitreal Bevacizumab with or without Macular Photocoagulation for Diabetic Macular Edema: A Meta-Analysis

  2018cites this paper
• Are the real‐life outcomes of using aflibercept in diabetic macular oedema comparable to the landmark studies?

  2018cites this paper
• Evaluation of systemic risk factors in different optical coherence tomographic patterns of diabetic macular edema.

  2018cites this paper
• Teratogenic Effects of Intravitreal Injection of Bevacizumab in a Pregnant Rat Model

  2017cites this paper
• Acircularity index and axis ratio of the foveal avascular zone in diabetic eyes and healthy controls measured by optical coherence tomography angiography☆

  2017cites this paper
• EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY

  2017cites this paper
• Multicenter, Randomized Clinical Trial to Assess the Effectiveness of Intravitreal Injections of Bevacizumab, Triamcinolone, or Their Combination in the Treatment of Diabetic Macular Edema.

  2017cites this paper
• Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Effective?

  2017cites this paper
• Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy.

  2017cites this paper
• Evaluation of effect of bevacizumab on central subfield macular thickness in the injected and contralateral (untreated) eye of patients with bilateral diabetic macular oedema

  2017cites this paper
• Intravitreal bevacizumab and dexamethasone implant for treatment of chronic diabetic macular edema

  2017cites this paper
• The treatment of diabetic macular edema: Current status and future perspectives

  2017cites this paper
• Efficacy of dexamethasone intravitreal implant for the treatment of persistent diffuse diabetic macular edema

  2017cites this paper
• Outcomes of intravitreal bevacizumab and macular photocoagulation for treatment of diabetic macular edema in a tertiary care eye hospital, Karachi

  2017cites this paper
• Étude des pratiques françaises dans la prise en charge de l’œdème maculaire diabétique

  2016cites this paper
• Classification of diabetic macular oedema using ultra-widefield angiography and implications for response to anti-VEGF therapy

  2016cites this paper
• A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.

  2016cites this paper
• A Systematic Review of Clinical Studies Using VEGF Inhibitors in the Treatment of Macular Edema from Diabetic Retinopathy

  2016cites this paper
• Anatomical and visual outcome of intravitreal bevacizumab (Avastin) in patients with diabetic macular edema.

  2016cites this paper
• Influência da adesão vitreomacular na resposta terapêutica do Edema macular diabético com antiangiogênicos

  2016cites this paper
• Ocular complications of diabetes mellitus.

  2015cites this paper
• Management of Vision-Threatening Complications of Vasoproliferative Tumors of the Retina

  2015cites this paper
• Anti-VEGF Molecules for the Management of Diabetic Macular Edema.

  2015cites this paper
• State of the art management of diabetic macular edema

  2015cites this paper
• The Effect of Intravitreal Bevacizumab Injection before Panretinal Photocoagulation in Patients with Clinically Significant Macular Edema

  2015cites this paper
• Pharmakologische Ansätze zur Behandlung des diabetischen Makulaödems

  2015cites this paper
• Intravitreal bevacizumab injection alone or combined with macular photocoagulation compared to macular photocoagulation as primary treatment of diabetic macular edema.

  2015cites this paper
• Primary intravitreal bevacizumab injection as a monotherapy versus combined intravitreal bevacizumab with argon laser photocoagulation in management of diabetic macular edema: A comparative study

  2015cites this paper
• Intravitreal Anti-VEGF Injections in Pregnancy: Case Series and Review of Literature

  2015cites this paper
• Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema

  2014cites this paper
• Effect of Macular Ischemia on Intravitreal Ranibizumab Treatment for Diabetic Macular Edema

  2014cites this paper
• Subtenon Vs Intravitreal Triamcinolone injection in Diabetic Macular Edema, A prospective study in Chinese population

  2014cites this paper
• TREATMENT OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR–RESISTANT DIABETIC MACULAR EDEMA WITH DEXAMETHASONE INTRAVITREAL IMPLANT

  2014cites this paper
• Bevacizumab and Diabetic Vitrectomy

  2014cites this paper
• EFFECTS OF INTRAVITREAL INJECTION OF BEVACIZUMAB ON INFLAMMATORY CYTOKINES IN THE VITREOUS WITH PROLIFERATIVE DIABETIC RETINOPATHY

  2014cites this paper
• Dexamethasone Intravitreal Implant in Vitrectomized Versus Nonvitrectomized Eyes for Treatment of Patients with Persistent Diabetic Macular Edema

  2014cites this paper
• Treatment of macular edema in diabetic retinopathy: comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections

  2014cites this paper
• Complications of Intravitreous Injections in Patients with Diabetes

  2014cites this paper
• Intravitreal injections and diabetic macular edema: actual and new therapeutic options.

  2013cites this paper
• Pharmacological Approach to Diabetic Macular Edema

  2013cites this paper
• Structural and Functional Measures of Efficacy in Response to Bevacizumab Monotherapy in Diabetic Macular Oedema: Exploratory Analyses of the BOLT Study (Report 4)

  2013cites this paper
• Prospective microperimetry and OCT evaluation of efficacy of repeated intravitreal bevacizumab injections for persistent clinically significant diabetic macular edema

  2013cites this paper
• Intravitreal Fasudil Combined with Bevacizumab for Treatment of Refractory Diabetic Macular Edema; a Pilot Study

  2013cites this paper
• Intravitreal bevacizumab treatment for refractory diabetic macular edema

  2013cites this paper
• Green-light fundus autofluorescence in diabetic macular edema.

  2013cites this paper
• Predictive factors for the progression of diabetic macular ischemia.

  2013cites this paper
• Diabetic macular edema: New promising therapies.

  2013cites this paper
• Long‐term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age‐related macular degeneration

  2013cites this paper
• Comparison of Intravitreal Triamcinolone Acetonide with Intravitreal Bevacizumab for Treatment of Diabetic Macular Edema: A Meta-analysis

  2013cites this paper
• Bevacizumab for the management of diabetic macular edema.

  2013cites this paper
• Ranibizumab in choroidal neovascularisation associated with ocular sarcoidosis

  2013cites this paper
• MACULAR LASER GRID ALONE VERSUS COMBINED WITH INTRAVITREAL TRIAMCINOLONE PLUS BEVACIZUMAB FOR DIABETIC MACULAR EDEMA

  2013cites this paper
• The use of vascular endothelial growth factor inhibitors (anti-VEGFs) for the treatment of diabetic retinopathy

  2013cites this paper
• Anti-VEGF Therapy for the Management of Diabetic Macular Edema

  2013cites this paper
• Diabetic Retinopathy: The Need for Predictive, Preventive and Personalized Approach to Management

  2013cites this paper
• Intravitreal double-dose ranibizumab therapy for refractory diabetic macular edema

  2013cites this paper
• Intravitreal Bevacizumab for Treatment of Diabetic Macular Oedema

  2013cites this paper
• Diabetic macular edema: new trends in management

  2012cites this paper
• Pathophysiology and treatment of diabetic retinopathy

  2012cites this paper
• Insight into 144 patients with ocular vascular events during VEGF antagonist injections

  2012cites this paper
• Triple therapy: Phaco-vitrectomy with ILM peeling, retinal endophotocoagulation, and intraoperative use of Bevacizumab for diffuse diabetic macular edema

  2012cites this paper
• Optical Coherence Tomographic Patterns in Diabetic Macula Edema Can Predict the Effects of Intravitreal Bevacizumab Injection as Primary Treatment

  2012cites this paper
• Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?

  2012cites this paper
• Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema

  2012cites this paper
• Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double‐blind study

  2012cites this paper
• Vision, Retinal Thickness, and Foveal Avascular Zone Size After Intravitreal Bevacizumab for Diabetic Macular Edema

  2012cites this paper
• Use of Anti-Vascular Endothelial Growth Factor Drugs for Diabetic Macular Edema

  2012cites this paper
• Ranibizumab and Other VEGF Antagonists for Diabetic Macular Edema

  2012cites this paper
• Management of Diabetic Macular Edema in Current Clinical Practice: A Review

  2012cites this paper